Funding research is not charity; it's our most powerful economic strategy. This is the message from Research Australia, the national peak body for health and medical research and innovation, as it calls for smarter investment in the country's health and medical research (HMR) sector. The organization argues that HMR should be treated as strategic public investment rather than discretionary spending, and that it is a key driver of economic growth and productivity.
The article highlights the importance of long-term planning and investment in research and innovation, rather than short-term political horizons. It points out that Australia has the potential to be a global contributor in developing and commercializing the next generation of diagnostics, therapies, and technologies that will define the future of healthcare. However, this potential is contingent on how the country invests in its HMR sector.
Research Australia's pre-Budget submission emphasizes the economic benefits of HMR, noting that for every $1 invested in HMR, the Australian economy gains around $4 in return. This is one of the highest returns of any government expenditure. The organization also highlights the social and fiscal dividends of HMR, such as avoiding preventable hospital admissions, enabling faster diagnoses, and exporting home-grown medical products.
The article also discusses the fragility of innovation pipelines, which depend on continuity, long-term planning, infrastructure, and stable investment across the research lifecycle. It argues that HMR and its workforce must be recognized as economic infrastructure, not a discretionary expense, if Australia is serious about transitioning from a resources-based economy to a knowledge-based one.
One of the key issues highlighted in the article is the underutilization of the Medical Research Future Fund (MRFF), a $24.5 billion endowment designed to provide $1 billion annually to fund transformative research. The article suggests that the fund could be disbursed more effectively, with costings released by the Parliamentary Budget Office showing that disbursements could be doubled to $1.4 billion annually without eroding the capital base. This would allow the MRFF to meet its original vision of sustaining Australian research while keeping the fund financially secure.
Research Australia also calls for a new research active healthcare mission to better support the translation and implementation of research and support clinician researchers and early- and mid-career researchers. The organization emphasizes the need for strategic investment in HMR, including trialling innovative co-investment models between industry, philanthropy, and government, and ensuring that investment and funding strategies are embedded in the work already underway through the National Health and Medical Research Strategy.
In conclusion, the article argues that funding medical research is not charity; it's our most powerful economic strategy. It calls for a bold and decisive approach to reimagining the role of public investment in HMR as a catalyst to deliver long-term and equitable social, economic, and productivity dividends. The organization emphasizes the need for a long-term perspective in research and innovation, where they are not the first to be cut in tight budgets, but the foundation upon which future prosperity is built.
